Healthcare Unfiltered Express

Episode 57: The KOMET-007 Trial

19 min · I går
episode Episode 57: The KOMET-007 Trial cover

Description

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.  A must listen - please share subscribe, and join the conversation.

Comments

0

Be the first to comment

Sign up now and become a member of the Healthcare Unfiltered Express community!

Get Started

1 month for 9 kr.

Then 99 kr. / month · Cancel anytime.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

All episodes

57 episodes